Hermann Tenor

USPTO Granted Patents = 13 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 8)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Radolfzell, DE (2010 - 2015)
Konstanz, CH (2020 - 2022)
Constance, DE (2016 - 2024)

Company Filing History:

Years Active: 2010-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12351585 - 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof (2025-07-08),

2. 11905293 - Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof (2024-02-20),

3. 11897890 - 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof (2024-02-13),

4. 11242347 - 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof (2022-02-08),

5. 11155558 - Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof (2021-10-26),

6. 10570137 - 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof (2020-02-25),

7. 9340522 - Pyrazolone-derivatives and their use as PDE-4 inhibitors (2016-05-17),

8. 9018175 - 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives (2015-04-28),

9. 8648100 - Roflumilast for the treatment of pulmonary hypertension (2014-02-11),

10. 8609848 - Pyrazolone-derivatives and their use as PDE-4 inhibitors (2013-12-17),

11. 8106047 - Triazolophthalazines (2012-01-31),

12. 7851472 - Triazolophthalazines (2010-12-14),

13. 7671050 - Triazolophthalazines (2010-03-02),

Title: Hermann Tenor: Innovator in Pharmaceutical Chemistry

Introduction

Hermann Tenor is a distinguished inventor based in Radolfzell, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as phosphodiesterase inhibitors. With a total of 13 patents to his name, Tenor's work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents are two notable inventions. The first is related to 2-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazinone derivatives, which are designed as phosphodiesterase inhibitors. This invention outlines compounds that can be utilized in treating diseases alleviated by the inhibition of PDE-5 in both humans and non-human mammals. The second patent focuses on dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors, further emphasizing his innovative approach to pharmaceutical development.

Career Highlights

Hermann Tenor has worked with prominent companies in the pharmaceutical industry, including Topadur Pharma AG and Takeda GmbH. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research and development in drug formulation.

Collaborations

Throughout his career, Tenor has collaborated with notable colleagues such as Dieter Flockerzi and Reto Naef. These partnerships have fostered an environment of innovation and have led to advancements in the field of pharmaceutical chemistry.

Conclusion

Hermann Tenor's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the industry. His work continues to pave the way for new therapeutic options and advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.